Opendata, web and dolomites

EwiSarc

A novel in vivo platform to study and target undruggable Ewing onco-chimera.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EwiSarc project word cloud

Explore the words cloud of the EwiSarc project. It provides you a very rough idea of what is the project "EwiSarc" about.

vivo    ex    protein    break    undruggable    ago    pediatric    force    initial    genes    convenient    leukemia    childhood    tear    lethality    onco    genetic    ideal    lacking    notably    easily    fli1    exported    disease    therapies    relatively    tremendous    innovative    platform    tumorigenic    exclusive    treatment    rate    classified    incidence    cells    ewing    chimeras    brain    tuning    cancer    chimeric    twenty    represented    tumor    sarcomas    balanced    degradation    point    strategies    accurately    vitro    view    efficient    characterization    though    ews    pharmacological    juvenile    lymphoma    million    therapeutic    patients    pockets    recapitulate    90    chimera    conventional    originating    types    transcription    event    hallmark    driving    form    sarcomagenesis    dogma    fusion    druggable    development    mortality    oncogenic    structure    mice    identification    fine    drastically    chromosomal    mechanisms    translocation    sarcoma    proteins    tumors    generation   

Project "EwiSarc" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI TRENTO 

Organization address
address: VIA CALEPINA 14
city: TRENTO
postcode: 38122
website: www.unitn.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://lunardilab.wordpress.com/killing-chimera-study-and-modelling-of-ewing-sarcoma/
 Total cost 180˙277 €
 EC max contribution 180˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) coordinator 180˙277.00

Map

 Project objective

Development of efficient therapeutic strategies in the past years has drastically reduced the lethality of several common types of pediatric and juvenile form of cancer such as leukemia, lymphoma and brain tumors. Such a tremendous success, however, does not include sarcomas treatment, whose mortality rate remains the same as twenty years ago. Ewing sarcoma is a childhood cancer with a relatively low incidence, with 3 cases/million/year. The initial oncogenic event is represented by a balanced chromosomal translocation originating a transcription factor chimeric onco-protein. Notably, 90% of Ewing sarcoma patients are characterized by the fusion between EWS and FLI1 genes. From a therapeutic point of view, as exclusive hallmark of tumor cells and driving force of the disease, the onco-chimera protein represents an ideal target, even though transcription factor onco-proteins are classified as “undruggable” from a conventional pharmacological point of view, lacking in their structure convenient targeting pockets. This project aims to break this dogma through the following steps: 1. Generation of an in vivo genetic platform based on an innovative ex vivo-in vitro-in vivo approach that will allow us to accurately recapitulate in mice Ewing sarcomagenesis; 2. Characterization in vivo and in vitro of those mechanisms and pathways that are essential for the tumorigenic process; and finally, 3. Identification of druggable targets whose fine-tuning will tear down Ewing sarcoma lethality by promoting onco-chimera degradation. The success of this project will not only lead to the development of new therapies against Ewing sarcoma, but also to the development of a novel platform which will be easily exported to other tumors driven by “undruggable” onco-chimeras.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EWISARC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EWISARC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MS4Drug (2019)

An Innovative Mass Spectrometry-Based Workflow for Drug Discovery

Read More  

TIPTOP (2019)

Tensoring Positive Maps on Operator Structures

Read More